{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-23-000045","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.929283+00:00","generated_at":"2026-06-18T06:22:57.333937+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MacroGenics sells TZIELD royalty to DRI for up to $200M; $100M upfront","bullets":["Upfront payment of $100M for single-digit royalty on global net sales of TZIELD.","MacroGenics retains a 50% share of royalty above an annual threshold.","Eligible for up to $50M milestone tied to TZIELD advancement in newly diagnosed type 1 diabetes.","Potential additional $50M if TZIELD achieves a specified net sales level.","Closing expected March 15, 2023; MacroGenics keeps other regulatory and commercial milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-23-000045","json":"https://secwatch.observer/filing/0001125345-23-000045.json","markdown":"https://secwatch.observer/filing/0001125345-23-000045.md","text":"https://secwatch.observer/filing/0001125345-23-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000045/0001125345-23-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000045/mgnx-20230308.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T06:22:57.333937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d7add6477e51e66df657ce653ac3ca8b6c02652","claim":"MACROGENICS INC entered into Purchase and Sale Agreement with DRI Healthcare Acquisitions LP valued at $100 million (effective 2023-03-08).","evidence_excerpt":"On March 8, 2023 (the “Execution Date”), MacroGenics, Inc. (the “Company”) entered into a Purchase and Sale Agreement (the “Royalty Purchase Agreement”) with DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, for the sale to DRI of the Company’s single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) (the “DRI Transaction”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000045/0001125345-23-000045-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"DRI Healthcare Acquisitions LP"},{"label":"Value","value":"$100 million"},{"label":"Effective","value":"2023-03-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}